News & Research

Find all the latest research, news and updates on Alzheimer’s disease blood-based biomarkers. Stay up to date with the latest educational materials from the BBM Workgroup.

The Global CEO Initiative on Alzheimer’s Disease Publishes the First Performance Recommendations for Blood-Based Biomarker Tests by Experts in the Field

Read the publication here

Read the plain language summary here

Read the press release

Featured

CEOi submits letter to CMS in response to their proposed reimbursement for brain health biomarkers

Advancing Patient Care: Clinician Awareness, Attitudes, and Interest in Blood Tests forAlzheimer’s Disease

Head-to-head Comparison of Leading Blood Tests for Alzheimer’s Disease Pathology

BBM Workgroup Activities & Educational Content:

News and Research

Oct 25, 2024

CEOi submits letter to CMS in response to their proposed reimbursement for brain health biomarkers

Oct 25, 2024

Jul 30, 2024

Advancing Patient Care: Clinician Awareness, Attitudes, and Interest in Blood Tests forAlzheimer’s Disease

Jul 30, 2024

Jun 12, 2024

Acceptable performance of blood biomarker tests of amyloid pathology — recommendations from the Global CEO Initiative on Alzheimer’s Disease

Jun 12, 2024

May 10, 2024

The Global CEO Initiative on Alzheimer’s Disease Comment on the World Health Organization’s Preferred Product Characteristics for Blood Tests for Alzheimer’s Disease

May 10, 2024

Mar 20, 2024

The Global CEO Initiative on Alzheimer’s Disease Announces Expansion of its Blood-Based Biomarker Workgroup in 2024

Mar 20, 2024

Mar 19, 2024

CEOi Blood-Based Biomarker Symposium at AAGP 2024

Mar 19, 2024

Filter by Category: Research articles | News | Press Releases | Workgroup Activities

Emily Scholler 10/25/24 Emily Scholler 10/25/24

CEOi submits letter to CMS in response to their proposed reimbursement for brain health biomarkers

Emily Scholler 10/23/24 Emily Scholler 10/23/24

WHO Preferred product characteristics of blood-based biomarker diagnostics for Alzheimer disease

Emily Scholler 9/13/24 Emily Scholler 9/13/24

Blood tests for Alzheimer’s disease in the era of anti-amyloid therapies

Emily Scholler 8/22/24 Emily Scholler 8/22/24

By Setting Standards, Experts Aim to Tame a Wild West of AD Blood Tests

Emily Scholler 8/7/24 Emily Scholler 8/7/24

Blood tests could soon predict your risk of Alzheimer’s

Emily Scholler 8/6/24 Emily Scholler 8/6/24

Plain Language Summary of “Acceptable performance of blood biomarker tests of amyloid pathology — recommendations from the Global CEO Initiative on Alzheimer’s Disease”

Emily Scholler 8/2/24 Emily Scholler 8/2/24

New blood tests can help diagnose Alzheimer's. Are doctors ready for what's next?

Emily Scholler 7/30/24 Emily Scholler 7/30/24

Advancing Patient Care: Clinician Awareness, Attitudes, and Interest in Blood Tests forAlzheimer’s Disease

Emily Scholler 7/28/24 Emily Scholler 7/28/24

Blood Biomarkers to Detect Alzheimer Disease in Primary Care and Secondary Care

Emily Scholler 6/26/24 Emily Scholler 6/26/24

Why There's New Hope in the Fight Against Alzheimer’s Disease

Emily Scholler 6/12/24 Emily Scholler 6/12/24

The Global CEO Initiative on Alzheimer’s Disease Publishes the First Performance Recommendations for Blood-Based Biomarker Tests by Experts in the Field

Emily Scholler 6/12/24 Emily Scholler 6/12/24

Head-to-head Comparison of Leading Blood Tests for Alzheimer’s Disease Pathology

Emily Scholler 6/12/24 Emily Scholler 6/12/24

Acceptable performance of blood biomarker tests of amyloid pathology — recommendations from the Global CEO Initiative on Alzheimer’s Disease

Emily Scholler 6/11/24 Emily Scholler 6/11/24

Alzheimer disease blood biomarkers: considerations for population-level use

Emily Scholler 5/10/24 Emily Scholler 5/10/24

The Global CEO Initiative on Alzheimer’s Disease Comment on the World Health Organization’s Preferred Product Characteristics for Blood Tests for Alzheimer’s Disease

Emily Scholler 5/10/24 Emily Scholler 5/10/24

FDA Will Regulate Diagnostic Tests. Yes, Those for Alzheimer’s, Too.

Emily Scholler 3/20/24 Emily Scholler 3/20/24

The Global CEO Initiative on Alzheimer’s Disease Announces Expansion of its Blood-Based Biomarker Workgroup in 2024

The Global CEO Initiative on Alzheimer’s Disease (CEOi) is excited to announce the second phase of its Blood-based Biomarker (BBM) Workgroup in 2024.

Knapsack 3/19/24 Knapsack 3/19/24

CEOi Blood-Based Biomarker Symposium at AAGP 2024

CEOi held a blood-based biomarker symposium at the American Association for Geriatric Psychiatry (AAGP) 2024 Annual Meeting, “Unleashing Diagnostic Innovation: Clinical Implementation of Blood-Based Biomarkers for Alzheimer’s Disease.”

Knapsack 3/7/24 Knapsack 3/7/24

Panel Discussion at AD/PD 2024

CEOi held a panel discussion on the sidelines of AD/PD 2024. The session was moderated by George Vradenburg, Convener of CEOi, and featured Ana Pereira, Mount Sinai; Robert Perneczky, University of Munich; and Richard Batrla, Eisai.

Emily Scholler 2/29/24 Emily Scholler 2/29/24

From St. Louis to Beijing: AD Biomarkers Change Similarly Before Symptoms

News & Research

Featured Stories

The Global CEO Initiative on Alzheimer’s Disease Publishes the First Performance Recommendations for Blood-Based Biomarker Tests by Experts in the Field

BBM Workgroup Activities & Educational Content:

CEOi submits letter to CMS in response to their proposed reimbursement for brain health biomarkers

WHO Preferred product characteristics of blood-based biomarker diagnostics for Alzheimer disease

Blood tests for Alzheimer’s disease in the era of anti-amyloid therapies

By Setting Standards, Experts Aim to Tame a Wild West of AD Blood Tests

Blood tests could soon predict your risk of Alzheimer’s

Plain Language Summary of “Acceptable performance of blood biomarker tests of amyloid pathology — recommendations from the Global CEO Initiative on Alzheimer’s Disease”

New blood tests can help diagnose Alzheimer's. Are doctors ready for what's next?

Advancing Patient Care: Clinician Awareness, Attitudes, and Interest in Blood Tests forAlzheimer’s Disease

Blood Biomarkers to Detect Alzheimer Disease in Primary Care and Secondary Care

Why There's New Hope in the Fight Against Alzheimer’s Disease

The Global CEO Initiative on Alzheimer’s Disease Publishes the First Performance Recommendations for Blood-Based Biomarker Tests by Experts in the Field

Head-to-head Comparison of Leading Blood Tests for Alzheimer’s Disease Pathology

Acceptable performance of blood biomarker tests of amyloid pathology — recommendations from the Global CEO Initiative on Alzheimer’s Disease

Alzheimer disease blood biomarkers: considerations for population-level use

The Global CEO Initiative on Alzheimer’s Disease Comment on the World Health Organization’s Preferred Product Characteristics for Blood Tests for Alzheimer’s Disease

FDA Will Regulate Diagnostic Tests. Yes, Those for Alzheimer’s, Too.

The Global CEO Initiative on Alzheimer’s Disease Announces Expansion of its Blood-Based Biomarker Workgroup in 2024

CEOi Blood-Based Biomarker Symposium at AAGP 2024

Panel Discussion at AD/PD 2024

From St. Louis to Beijing: AD Biomarkers Change Similarly Before Symptoms

Navigation

Follow Us